Patents Assigned to Jounce Therapeutics, Inc.
  • Anti-PD-1 antibodies and uses thereof
    Patent number: 11905329
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: June 7, 2022
    Date of Patent: February 20, 2024
    Assignee: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Compositions and Methods for Vaccination and the Treatment of Infectious Diseases
    Publication number: 20230151098
    Abstract: Methods of treating infectious diseases, such as a viral diseases, and methods of enhancing the effectiveness of a vaccine against an infectious disease, such as a viral disease, with an ICOS agonist, such as an anti-ICOS agonist antibody, are provided.
    Type: Application
    Filed: April 19, 2021
    Publication date: May 18, 2023
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Christopher Harvey, Richard Murray, Robert Huebner
  • Anti-PD-1 Antibodies and Uses Thereof
    Publication number: 20230018445
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: June 7, 2022
    Publication date: January 19, 2023
    Applicant: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Methods of Treating Cancer with Anti-PD-1 Antibodies
    Publication number: 20220378909
    Abstract: Methods of treating cancer with anti-PD-1 antibodies are provided.
    Type: Application
    Filed: November 4, 2020
    Publication date: December 1, 2022
    Applicant: Jounce Therapeutics, Inc.
    Inventor: Jian Xu
  • Compositions and Methods for the Treatment of Cancer (Anti-ICOS Antibody Dosing)
    Publication number: 20220281978
    Abstract: Methods of treating cancer with particular doses of anti-ICOS antibodies are provided.
    Type: Application
    Filed: December 14, 2021
    Publication date: September 8, 2022
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Jason Windham Reeves, Deborah Law, Christopher Harvey, Elizabeth G. Trehu, Lauren Pepper MacKenzie, Amit Deshpande, Jennifer S. Michaelson, Igor Feldman, Sriram Sathyanarayanan
  • Anti-PD-1 antibodies and uses thereof
    Patent number: 11384147
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: July 12, 2022
    Assignee: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Antibodies to LILRB2
    Patent number: 11359019
    Abstract: Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: June 14, 2022
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Heather B. Cohen, Lauren Pepper Mackenzie, Donald Raymond Shaffer, Jeffrey Yan-Fei Smith
  • Anti-ICOS Antibodies for the Treatment of Cancer
    Publication number: 20220135682
    Abstract: Methods of treating cancer with multiple doses of anti-ICOS antibodies and multiple doses of anti-CTLA4 antibodies are provided.
    Type: Application
    Filed: March 10, 2020
    Publication date: May 5, 2022
    Applicant: Jounce Therapeutics, Inc.
    Inventor: Christopher Harvey
  • Methods of treating cancer in a subject having elevated ICOS and/or T-bet levels of CD+4 cells by administering an ICOS agonist
    Patent number: 11292840
    Abstract: The invention provides methods of treating cancer and methods for selecting treatment approaches for cancer.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: April 5, 2022
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Christopher Harvey, Deborah Law, Amanda Elizabeth Hanson, Martin Yu Fan
  • Methods of Treating Cancer
    Publication number: 20210355222
    Abstract: The present disclosure provides methods of treating cancer and methods for selecting treatment approaches for cancer.
    Type: Application
    Filed: October 25, 2019
    Publication date: November 18, 2021
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Lara Lewis McGrath, Christopher Harvey, Deborah Law, Amanda Hanson
  • Methods of Treating Cancer
    Publication number: 20210353750
    Abstract: The present disclosure provides methods of treating cancer and methods for selecting treatment approaches for cancer.
    Type: Application
    Filed: October 18, 2019
    Publication date: November 18, 2021
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Heather Hirsch, Deborah Law
  • Gene Signatures for Determining ICOS Expression
    Publication number: 20210340256
    Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.
    Type: Application
    Filed: February 5, 2021
    Publication date: November 4, 2021
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Jason Windham Reeves, Igor Feldman, Christopher Harvey, Sriram Sathyanarayanan, Heather Hirsch, Lauren Pepper MacKenzie, Amit Deshpande, Stephen Sazinsky, Jennifer S. Michaelson, Kutlu Goksu Elpek
  • Antibodies to ICOS
    Publication number: 20210171635
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: September 16, 2020
    Publication date: June 10, 2021
    Applicant: Jounce Therapeutics, Inc.
    Inventors: Stephen Sazinsky, Jennifer S. Michaelson, Sriram Sathyanarayanan, Kutlu Goksu Elpek
  • Gene signatures for determining ICOS expression
    Patent number: 10968277
    Abstract: Gene expression signatures correlating to ICOS expression levels are provided. Methods of treatment comprising determining ICOS expression levels using gene signatures in patients and administering anti-ICOS antibodies are also provided.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: April 6, 2021
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Jason Windham Reeves, Igor Feldman, Christopher Harvey, Sriram Sathyanarayanan, Heather Hirsch, Lauren Pepper MacKenzie, Amit Deshpande, Stephen Sazinsky, Jennifer S. Michaelson, Kutlu Goksu Elpek
  • Anti-PD-1 Antibodies and Uses Thereof
    Publication number: 20200399374
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Application
    Filed: April 10, 2020
    Publication date: December 24, 2020
    Applicant: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Antibodies to LILRB2
    Patent number: 10723798
    Abstract: Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 28, 2020
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Heather B. Cohen, Lauren Pepper Mackenzie, Yasmin Ramsay, Donald Raymond Shaffer, Jeffrey Yan-Fei Smith
  • Antibodies to PD-1 and uses thereof
    Patent number: 10654929
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: May 19, 2020
    Assignee: Jounce Therapeutics, Inc.
    Inventors: George Robert Mabry, III, Stephen Sazinsky
  • Methods of treating conditions with antibodies that bind B7-H4
    Patent number: 10626176
    Abstract: Provided herein are embodiments relating to therapeutic applications of B7-H4 antibodies.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: April 21, 2020
    Assignee: JOUNCE THERAPEUTICS, INC.
    Inventors: Sriram Sathyanarayanan, Tatiana Novobrantseva, Virna Cortez-Retamozo
  • Antibodies to LILRB2
    Patent number: 10618961
    Abstract: Provided herein are various embodiments relating to antibodies that bind LILRB2. Anti-LILRB2 antibodies can be used in methods to treat disease, for example, cancer.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: April 14, 2020
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Heather B. Cohen, Lauren Pepper Mackenzie, Yasmin Ramsay, Donald Raymond Shaffer, Jeffrey Yan-Fei Smith, Kristin Shanea O'Malley, Kevin Patrick Guay
  • Antibodies to ICOS
    Patent number: 10570203
    Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: February 25, 2020
    Assignee: Jounce Therapeutics, Inc.
    Inventors: Stephen Sazinsky, Jennifer S. Michaelson, Sriram Sathyanarayanan, Kutlu Goksu Elpek